Incorporating Traditional Chinese Medicine Syndrome Differentiation in Randomized Trials: Methodological Issues (Cochrane CAM Field Invited Commentary)  by Ho, Robin et al.
Integr Med Res ( 2 0 1 5 ) 42–144 124
tions, the potential of network meta-analysis should be
explored.
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Purpose: In traditional Chinese medicine (TCM) practice,
decision on prescription is based on a process called Bian
Zheng Lun Zhi (syndrome differentiation guided treatment
decision). The syndrome differentiation process may not
be recognized in conventional standards of randomized
controlled trial (RCT), limiting the model validity and general-
izability of results.
Methods: This article discussed how syndrome differ-
entiation, a classical TCM approach in diagnosis, can be
incorporated into RCT design.
Results: Four methodological solutions were proposed: (i)
Lesson learnt from the design of patient reported outcome
questionnaire can inform how TCM diagnosis instrument
could be developed. A proper TCM diagnostic tool with sound
psychometric properties can reduce variation in the syndrome
differentiation process. (ii) Treatment strategies for a speciﬁc
TCM diagnosis could be highly diversiﬁed. Delphi technique
can inform the design of optimal treatment program by facil-
itating consensus among experts. (iii) Subgroup analysis is
often needed in RCT recruiting patient with several TCM
diagnosis. It is highlighted that investigators should consider
whether the design, analysis and context of the trial are robust
enough to support a reliable claim of subgroup effect associ-
ated with a particular TCM diagnosis. (iv) Finally, we discussed
alternative research and analysis approaches for handling
misalignment of Western and TCM diagnoses, including the
possibility of unifying TCM syndrome with Western pheno-
types using latent class analysis.
Conclusion: Further methodological advances are needed
in the better alignment of classical TCM theories and diagnos-
tic instrument development, as well as in reducing bias during
the expert consensus processes.
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Purpose: Chinese herbal medicine (CHM) has been increas-
ingly used as an adjuvant treatment for multi-drug resistant
tuberculosis (MDR-TB) in China. To inform clinical practice,
we performed a systematic review on the beneﬁcial effect and
safety of CHM for MDR-TB.
Methods: We systematically searched the six electronic
databases for randomised clinical trials (RCTs) of CHM plus
chemotherapy for MDR-TB. RevMan 5.2 software was used for
data analyseswith effect estimates presented as risk ratio (RR)
with 95% conﬁdence interval (CI).
Results: 28 RCTs involving 3085 participants with MDR-
TB were included. The methodological quality was generally
poor in terms of risk of bias. Meta-analyses favoured CHM
plus chemotherapy on sputum bacteriological conversion rate
compared with chemotherapy alone after initiation of treat-
ment (6th months: RR 1.29, 95% CI 1.14 to 1.46, n=11; 12th
months: RR 1.38, 95%CI 1.19 to 1.59, n=5; 18thmonths: RR 1.19,
95% CI 1.11 to 1.28, n=7). Compared with chemotherapy alone,
meta-analysis showed beneﬁt from CHM plus chemotherapy
on lung lesions absorption rate (12th months: RR 1.26, 95% CI
1.09 to 1.46, n=3; 18th months: RR 1.18, 95%CI 1.07 to 1.30, n=6)
andpulmonary cavity closure rate by radiological examination
(18th months: RR 1.24, 95%CI 1.01 to 1.51; n=4), relapse rate (RR
0.28, 95%CI 0.16 to 0.50, n=4), and abnormal liver function (RR
0.56, 95% CI 0.46 to 0.69, n=14).
Conclusion: CHM as an adjuvant to anti-TB chemotherapy
may have beneﬁcial effect for MDR-TB in terms of bacteriolog-
ical and radiological outcomes, and is safe. However, due to
poor methodology of the included trials, a conﬁrmative con-
clusion needs to be supported through further robust clinical
trial.
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